Solid Biosciences (SLDB) Liabilities and Shareholders Equity (2017 - 2024)
Historic Liabilities and Shareholders Equity for Solid Biosciences (SLDB) over the last 8 years, with Q3 2024 value amounting to $211.8 million.
- Solid Biosciences' Liabilities and Shareholders Equity rose 1466.91% to $211.8 million in Q3 2024 from the same period last year, while for Dec 2024 it was $691.5 million, marking a year-over-year decrease of 1179.63%. This contributed to the annual value of $164.9 million for FY2023, which is 3662.33% down from last year.
- Per Solid Biosciences' latest filing, its Liabilities and Shareholders Equity stood at $211.8 million for Q3 2024, which was up 1466.91% from $231.0 million recorded in Q2 2024.
- Over the past 5 years, Solid Biosciences' Liabilities and Shareholders Equity peaked at $285.3 million during Q1 2021, and registered a low of $40.5 million during Q3 2020.
- For the 5-year period, Solid Biosciences' Liabilities and Shareholders Equity averaged around $195.4 million, with its median value being $208.5 million (2022).
- As far as peak fluctuations go, Solid Biosciences' Liabilities and Shareholders Equity tumbled by 6905.27% in 2020, and later skyrocketed by 51450.71% in 2021.
- Quarter analysis of 5 years shows Solid Biosciences' Liabilities and Shareholders Equity stood at $171.2 million in 2020, then soared by 35.76% to $232.4 million in 2021, then increased by 11.99% to $260.3 million in 2022, then plummeted by 36.62% to $164.9 million in 2023, then rose by 28.43% to $211.8 million in 2024.
- Its last three reported values are $211.8 million in Q3 2024, $231.0 million for Q2 2024, and $248.7 million during Q1 2024.